The European Federation of Pharmaceutical Industries and Associations (EFPIA or “the Federation”) authoritatively announced its newly-sanctioned and extremely predictable Disclosure Code (termed as the “Code”), on July 2, 2013. The Code is about the responsibilities of the EFPIA member companies and the companies that are the members of an EFPIA member association to monitor and manage HCP & HCO spend tracking.
EFPIA is a compact and a strong association of nearly forty individual pharmaceutical manufacturers spread across thirty European nations. Though the organization operates through a two-way channel, EFPIA’s codes and policies apply to roughly 1,900 pharmaceutical manufacturers. The EFPIA body is so powerful and expansive that it is able to exercise substantial influence over all the European pharmaceutical codes and, subsequently, over almost every pharmaceutical manufacturers operating in Europe.
The Code states that each manufacturer (which includes both EFPIA manufacturer members and members of EFPIA association members) is compelled to track down transfers of value related to the human prescribed drugs, at three distinctive levels. Firstly, at the aggregate level, secondly at the individual HCO level and thirdly at the individual HCP level.
For monitoring spend tracking analytics and reporting at the aggregate level, the transfers of value must pertain to the research and development of clinical trials, non-clinical lessons and non-Interventional studies that involve the collection of patient data from or on behalf of individual, or groups of HCPs, explicitly for the training.
The individual HCP & HCO spend tracking is done on the donations & Grants to HCOs, the involvement of costs on various events, registration fees, the cost incurred by HCOs and third parties appointed by HCOs while managing an event and fee-for-service & consultancy respectively.
The stringent methodologies under the code have been put into action since January 1st, 2015, but there have been several rooms kept for minor amendments and alteration like that of tracking down costs incurred for “meals and drinks” and low-priced items of medical utility.
EFPIA is a compact and a strong association of nearly forty individual pharmaceutical manufacturers spread across thirty European nations. Though the organization operates through a two-way channel, EFPIA’s codes and policies apply to roughly 1,900 pharmaceutical manufacturers. The EFPIA body is so powerful and expansive that it is able to exercise substantial influence over all the European pharmaceutical codes and, subsequently, over almost every pharmaceutical manufacturers operating in Europe.
The Code states that each manufacturer (which includes both EFPIA manufacturer members and members of EFPIA association members) is compelled to track down transfers of value related to the human prescribed drugs, at three distinctive levels. Firstly, at the aggregate level, secondly at the individual HCO level and thirdly at the individual HCP level.
For monitoring spend tracking analytics and reporting at the aggregate level, the transfers of value must pertain to the research and development of clinical trials, non-clinical lessons and non-Interventional studies that involve the collection of patient data from or on behalf of individual, or groups of HCPs, explicitly for the training.
The individual HCP & HCO spend tracking is done on the donations & Grants to HCOs, the involvement of costs on various events, registration fees, the cost incurred by HCOs and third parties appointed by HCOs while managing an event and fee-for-service & consultancy respectively.
The stringent methodologies under the code have been put into action since January 1st, 2015, but there have been several rooms kept for minor amendments and alteration like that of tracking down costs incurred for “meals and drinks” and low-priced items of medical utility.